leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 01:14:05 - browse：7

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

Let's speed up science by embracing open access publishing

Shifting the focus from loneliness to social health

Woman returns to dialysis after doctors remove transplanted pig kidney

A letter from the executive editor: STAT UnitedHealth investigation

ASCO: Palliative care found as helpful given virtually as in person

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

leisure time

leisure time

New air purifier tech could be key to improving indoor air quality

With trial win, GSK could get blood cancer drug back on market

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What is STAT's opinion section for?

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

State Dept. review finds Biden bears some blame for Afghanistan failures

Kaiser's Risant Health gobbled up Geisinger. Who is next?

entertainment

Change Healthcare can notify patients about the breach, HHS says

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Medicare’s new pay boost for primary care is angering specialists

Weight loss drugs should be covered by insurers, AMA says

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

explore

explore

Wikipedia

explore